Earnings summaries and quarterly performance for Citius Pharmaceuticals.
Executive leadership at Citius Pharmaceuticals.
Board of directors at Citius Pharmaceuticals.
Research analysts covering Citius Pharmaceuticals.
Recent press releases and 8-K filings for CTXR.
Citius Pharmaceuticals, Inc. Reports FY 2025 Financial Results and LYMPHIR Launch
CTXR
Earnings
Product Launch
New Projects/Investments
- Citius Pharmaceuticals, Inc. reported a net loss of $39.7 million, or ($3.38) per share, for the fiscal year ended September 30, 2025.
- Its subsidiary, Citius Oncology, launched LYMPHIR™ in the U.S. in December 2025 for the treatment of adult patients with relapsed or refractory Stage I-III CTCL.
- As of September 30, 2025, the company held $4.3 million in cash and cash equivalents.
- Citius Pharma and Citius Oncology collectively raised approximately $61 million in gross proceeds from strategic financings during and after the fiscal year end.
Dec 23, 2025, 9:49 PM
Citius Pharmaceuticals Reports Fiscal Year 2025 Results and LYMPHIR Launch
CTXR
Earnings
Product Launch
New Projects/Investments
- Citius Pharmaceuticals' subsidiary, Citius Oncology, launched LYMPHIR™ in the U.S. in December 2025 for the treatment of relapsed or refractory Stage I-III CTCL, following its FDA approval.
- For the fiscal year ended September 30, 2025, Citius Pharma reported no revenues and a net loss of $39.7 million, or ($3.38) per share.
- The company's cash and cash equivalents stood at $4.3 million as of September 30, 2025.
- Citius Pharma and its subsidiary, Citius Oncology, collectively raised approximately $61 million in gross proceeds from strategic financings during and after the fiscal year ended September 30, 2025.
Dec 23, 2025, 9:30 PM
Citius Oncology Announces Commercial Launch of LYMPHIR
CTXR
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- Citius Oncology, a 79% majority-owned subsidiary of Citius Pharmaceuticals, Inc., commercially launched LYMPHIR™ (denileukin diftitox-cxdl) on December 1, 2025, for the treatment of adult patients with relapsed or refractory Stage I–III cutaneous T-cell lymphoma (CTCL).
- LYMPHIR is the first marketed product for Citius Oncology, targeting an estimated U.S. market valued at over $400 million.
- The FDA approved LYMPHIR in August 2024, and it has been assigned a permanent J-code (J9161), effective April 1, 2025, to facilitate reimbursement and streamline claims processing.
- Citius Pharmaceuticals' broader pipeline includes Mino-Lok®, which achieved positive topline data in its Phase 3 trial in 2024, and Halo-Lido, which completed its Phase 2b trial in 2023 with positive results.
Dec 1, 2025, 10:03 PM
Citius Pharmaceuticals Announces Closing of $6.0 Million Registered Direct Offering
CTXR
New Projects/Investments
Product Launch
- Citius Pharmaceuticals Inc. announced and closed a registered direct offering on October 21, 2025, generating approximately $6.0 million in gross proceeds.
- The offering included the sale of 3,973,510 shares of common stock (or pre-funded warrants) and accompanying common warrants, at a purchase price of $1.51 per share.
- The common warrants have an exercise price of $1.40 per share and will expire five years from the initial exercise date. Pre-funded warrants are exercisable at $0.0001 per share.
- The company expects net proceeds of approximately $5.5 million, which will be used to support the commercial launch of LYMPHIR™, fund development initiatives for product candidates, and for general corporate purposes.
- H.C. Wainwright & Co. served as the exclusive placement agent, receiving a 7.0% cash fee of the gross proceeds and warrants to purchase up to 278,146 shares at an exercise price of $1.8875 per share.
Oct 21, 2025, 8:41 PM
Citius Pharmaceuticals Closes $6.0 Million Registered Direct Offering
CTXR
New Projects/Investments
- Citius Pharmaceuticals Inc. (CTXR) announced the closing of a registered direct offering on October 21, 2025, generating approximately $6.0 million in gross proceeds.
- The offering involved the sale of 3,973,510 shares of common stock (or pre-funded warrants) and accompanying common warrants, priced at $1.51 per share.
- The net proceeds are intended to support the commercial launch of LYMPHIR™, which received FDA approval in August 2024, as well as other product development initiatives and general corporate purposes.
Oct 21, 2025, 8:30 PM
Citius Pharmaceuticals Announces Registered Direct Offering
CTXR
New Projects/Investments
Product Launch
- Citius Pharmaceuticals has entered into a definitive agreement for a registered direct offering of 3,973,510 shares of its common stock (or pre-funded warrants) and accompanying common warrants.
- The purchase price for each share (or pre-funded warrant) and accompanying common warrant is $1.51, with the common warrants having an exercise price of $1.40 per share.
- The offering is expected to generate approximately $6.0 million in aggregate gross proceeds for the company.
- The net proceeds are intended to support the commercial launch of LYMPHIR™, fund development initiatives for product candidates, and cover general corporate purposes.
- The closing of the offering is anticipated on or about October 21, 2025.
Oct 21, 2025, 12:00 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more